J Law Med Ethics. 2021;49(1):39-49. doi: 10.1017/jme.2021.8.
Enhancing research and development and ensuring equitable pricing and access to cutting-edge treatments are both vital to a biopharmaceutical innovation system that works in the public interest. However, despite delivering numerous therapeutic advances, the existing system suffers from major problems: a lack of directionality to meet key needs, inefficient collaboration, high prices that fail to reflect the public contribution, and an overly-financialized business model.
加强研究与开发,并确保公平定价和获得尖端治疗,这对于一个符合公共利益的生物医药创新体系至关重要。然而,尽管取得了许多治疗进展,但现有体系仍存在重大问题:缺乏方向性以满足关键需求、协作效率低下、价格过高,未能反映公共贡献,以及过度金融化的商业模式。